drug induced hypertransaminasemia. abnormal serum enzyme levels
Conditions
Interventions
Intervention 1: prescription of Folic acid as placebo in dose of 1mg/day in drug-induced hypertransaminasemia. Intervention 2: prescription of Ursodeoxy cholic acid in dose of 10mg/kg/day in drug
Treatment - Drugs
prescription of Folic acid as placebo in dose of 1mg/day in drug-induced hypertransaminasemia
prescription of Ursodeoxy cholic acid in dose of 10mg/kg/day in drug induced hypertransaminasemia
prescription of Silymarin in dose of 5mg/kg/day for anticonvulsive induced hypertransaminasemia
prescription of Vitamin E in dose of 1mg or IU/kg/day up to 50mg/day for drug induced hypertransaminasemia
Sponsors
Vice-chancellor for research-Medical school of Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
4 Months to 13 Years
Inclusion criteria
Inclusion criteria: Patients with age between 4 months to 13 years in pediatric neurology ward and clinic of Valiasr hospital with anticonvulsive induced hypertransaminasemia after rule out of common causes of hepatitis such as viral, autoimmune, metabolic and after rule out of anatomical defects have been included. Any patient without parents consent was excluded and any patient with spontaneous decline in transaminases were excluded too.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transaminases levels. Timepoint: one month after intervention and one month after cessation of it. Method of measurement: serum transaminases with one standard kit and in International Unite per litre. | — |
Secondary
| Measure | Time frame |
|---|---|
| No rebound elevation of serum transaminases after cessation of intervention. Timepoint: one month after intervention cessation. Method of measurement: with standard lab kit and in International Unite per litre. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoumeh Asgarshirazi
School of Medicine,Tehran University of Medical Sciences
Outcome results
None listed